1. The Increasing Responsibility of the Urologist in Maintaining Bone Health in Prostate Cancer Patients 
Kurt Miller 
European Urology Supplements 
Volume 5, Issue 7, Pages (April 2006)
DOI: /j.eursup
Copyright © Terms and Conditions

2. Fig. 1
Risk of developing osteoporosis after ADT is initiated in osteopenic men with hormone-refractory prostate cancer. LHRH=Luteinizing hormone-releasing hormone. From Weston et al. [1], with permission.
European Urology Supplements 2006 5, DOI: ( /j.eursup )
Copyright © Terms and Conditions

3. Fig. 2
BMD changes after 12 months of ADT. GnRH=Gonadotropin-releasing hormone; GnRH-a=GnRH analogue. From Mittan et al. [2], with permission.
European Urology Supplements 2006 5, DOI: ( /j.eursup )
Copyright © Terms and Conditions

4. Fig. 3
Kaplan–Meier estimate of fracture-free survival by type of treatment. GnRH=Gonadotropin-releasing hormone. From Shahinian et al. [3], with permission.
European Urology Supplements 2006 5, DOI: ( /j.eursup )
Copyright © Terms and Conditions

5. Fig. 4
Mean percent change from baseline BMD during ADT and pamidronate therapy. Data from Smith et al. [5].
European Urology Supplements 2006 5, DOI: ( /j.eursup )
Copyright © Terms and Conditions

6. Fig. 5
Mean percent change from baseline lumbar spine BMD during zoledronic acid treatment at one year. GnRH=Gonadotropin-releasing hormone. Data from Smith et al. [6].
European Urology Supplements 2006 5, DOI: ( /j.eursup )
Copyright © Terms and Conditions

7. Fig. 6
Mean percent change from baseline hip bone BMD during zoledronic acid treatment at one year. From Smith et al. [6], with permission.
European Urology Supplements 2006 5, DOI: ( /j.eursup )
Copyright © Terms and Conditions